Acticor Biotech announced the results of its collaboration with Brainomix Limited, to further explore the imaging datausing Artificial Intelligence (AI) from its phase 1b/2a ACTIMIS study. The ACTIMIS clinical trial evaluating glenzocimab in combination with the reference treatment (thrombolysis with or without thrombectomy) in patients presenting with Acute Ischemic Stroke (AIS) has demonstrated a favorable safety profile of glenzocimab, as well as a significant reduction in the number of intracerebral hemorrhages and mortality in the group treated with glenzocimab. To explore the mode of action of glenzocimab in the reduction of intracranial hemorrhage occurrence, a collaboration has been setup with Brainomix, a UK company specialized in the creation of AI-powered imaging biomarkers, to further analyze imaging stroke results from ACTIMIS study.

In a post-hoc analysis of the ACTIMIS study results, ischemic injury and hemorrhagic transformation volume measurements were quantified using AI-enabled Brainomix software. This provided an objective assessment of the evolution of the stroke brain injury which was associated with clinical outcome. First results using these biomarkers showed that patients treated with glenzocimib had smaller stroke lesion volumes compared to placebo-recipients (standard of care only), mainly due to a significant reduction in hemorrhagic transformation volumes.

The benefit of glenzocimab was more pronounced in patients having undergone a mechanical thrombectomy after an initial treatment by a thrombolytic agent.